XOMA Royalty (XOMA) Other Operating Expenses (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Other Operating Expenses came in at $27000.0 in Q1 2026, up 100.42% year-on-year from $13472.0 in Q1 2025, and up 100.27% quarter-over-quarter from -$10.1 million in Q4 2025.
XOMA Royalty (XOMA) Other Operating Expenses (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Other Operating Expenses across 14 years of filings, most recently posting $27000.0 for Q1 2026.
- Other Operating Expenses for Q1 2026 came in at $27000.0, up 100.42% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.9 million (down 2342.44% YoY), and the FY2025 annual result was -$26.5 million, down 6569.27% from the prior year.
- Other Operating Expenses came in at $27000.0 for Q1 2026 at XOMA Royalty, up from -$10.1 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $7.0 million in Q3 2024 to a low of -$10.1 million in Q4 2025.
- The 5-year median for Other Operating Expenses is -$618000.0 (2024), against an average of -$2.0 million.
- Across the five-year window, Other Operating Expenses slumped 3236.89% in 2024 and jumped 100.42% in 2026, its largest moves.
- XOMA Royalty's Other Operating Expenses stood at $97000.0 in 2022, then surged by 1754.64% to $1.8 million in 2023, then decreased by 8.73% to $1.6 million in 2024, then tumbled by 714.13% to -$10.1 million in 2025, then jumped by 100.27% to $27000.0 in 2026.
- The last three Other Operating Expenses figures came in at $27000.0 (Q1 2026), -$10.1 million (Q4 2025), and -$4.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | -10.08 Mn |
| Sep 30, 2025 | -4.48 Mn |
| Jun 30, 2025 | -5.33 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 7.01 Mn |
| Jun 30, 2024 | -1.26 Mn |
| Mar 31, 2024 | -7.06 Mn |
| Jun 30, 2023 | 1.80 Mn |
| Mar 31, 2023 | 225,000.00 |
| Dec 31, 2022 | 97,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Dec 31, 2018 | -543,000.00 |
| Dec 31, 2017 | -1,000.00 |
| Jun 30, 2017 | -1.46 Mn |
| Mar 31, 2017 | -2.02 Mn |
| Dec 31, 2016 | -4.55 Mn |
| Jun 30, 2016 | 21,000.00 |
| Mar 31, 2016 | -36,000.00 |